Also known as Body Protective Compound 157 · PL 14736
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
BPC-157 is a 15-amino-acid sequence derived from a protective protein found in human gastric juice. Preclinical work suggests pro-angiogenic and cytoprotective activity across tendon, ligament, muscle, and GI tissue.
BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid sequence derived from a protective protein identified in human gastric juice. It is studied as a cytoprotective and pro-angiogenic agent, with most of the interest centered on connective-tissue and gastrointestinal repair.
Essentially all of the evidence is preclinical — cell cultures and rodent models — and BPC-157 is not approved by the FDA for any use. It is widely discussed in the tissue-repair literature but lacks the controlled human trials that characterize approved peptides, so model choice and endpoint definition are central caveats.
Putative upregulation of VEGFR2 and modulation of nitric oxide / growth factor pathways.
Behind every vial of BPC-157 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how BPC-157, specifically, is brought into being.
On paper, BPC-157 is C62H98N16O22 — about 1,419.5 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling BPC-157 means roughly 15 coupling cycles on the synthesizer — one protected residue added at a time, which is also 15 chances for an incomplete coupling to seed a deletion impurity.
The crude mixture — BPC-157 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of BPC-157 proves itself: identity confirmed by mass spectrometry against its ~1,419.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of BPC-157 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
At 15 residues BPC-157 is a comparatively short synthesis, which makes it cheap to produce — and cheap to fake. The short, low-cost sequence is exactly why the market is flooded with under-characterized material; a batch-specific certificate of analysis is the only way to tell real from filler.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in gastric juice, studied in preclinical models for tissue repair and cytoprotection.
Research contexts include tendon, ligament, and muscle repair, gastrointestinal protection, and angiogenesis — almost entirely in cell and animal models.
No. BPC-157 is not approved for any medical use and the evidence base is preclinical. This page is a research and educational reference only.
Studies point to upregulation of the VEGFR2 receptor and modulation of nitric-oxide and growth-factor pathways, though the mechanism is not fully established.